Bargain hunters lifted shares of Synta Pharmaceucticals Corp. (Nasdaq: SNTA) $1.19 to close at $2.55. The stock price collapsed last week after the company suspended a late stage clinical trial of its cancer treatment elesclomol due to safety concerns
